Hairy Cell Leukemia Market by Therapies (Chemotherapy and Targeted Therapy) and Regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global hairy cell leukemia market size is anticipated to expand at a robust CAGR during the forecast period, 2021-2028. The growth of the market is attributed to rising awareness about the hairy cell leukemia coupled with rising disposable income. Moreover, increasing diagnosis rate of hairy cell leukemia is driving the market growth.
Hairy cell leukemia is a rare type of blood cancer that is caused due to abnormal growth of B- cells. The outgrown B cells or B lymphocyte when examined under a microscope looks similar to hair extending from the surface area, which gives the cancer its name. Hairy cell leukemia is characterized by the uncontrolled accumulation of lymphocytes by bone marrow.
Most of the affected individuals are males 50 years of age or older. Early diagnosis can help the patients live longer. There are advanced diagnostic tests to detect the hairy cell leukemia. In one of the diagnostic tests, the blood profile indicates the total number of lymphocytes, which indicates the disease. Physicians can easily diagnose the cancer by physical examination. Most of the patients also require bone marrow biopsy for confirmation.
Market Trends, Drivers, Restraints, and Opportunities:
- Increasing R&D activities for the development of advanced therapy is driving the growth of the market.
- Ongoing technological developments is expected to augment the hairy cell leukemia market growth.
- High cost for the treatment can act as a major restraint for the market growth.
- Efficiency of the treatment available is yet to be discover, limiting the market growth.
- State government bodies are implementing programs to increase the awareness about the cancer, which is stimulating the growth of the market.
- The presence of reimbursement programs is speculated to propel the hairy cell leukemia market.
Scope of the Report
The report on the global hairy cell leukemia market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Hairy Cell Leukemia market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Therapies (Chemotherapy and Targeted Therapy) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Hoffmann-La Roche Ltd, Janssen Global Services LLC, Dr.Reddy's Laboratories, Emcure Pharmaceuticals, Amgen Inc., Hospira, Astex Therapeutics, Pfizer Inc, AstraZeneca plc, BioGenomics Limited, Incyte Corp, Merck & Co Inc, Genentech, bluebird bio, Beam Therapeutics, Mission Bio, Roivant Sciences Inc., Humanigen, Fate Therapeutics, Kronos Bio, Tasso, PTC Therapeutics, Quantgene, Syros Pharmaceuticals, Oncoternal, GlycoMimetics, Notable Labs, Nuprobe, CARsgen, and Twinstrand Biosciences Inc. |
Hairy Cell Leukemia Market Segment Insights:
Chemotherapy segment to grow at a rapid pace
Based on therapies, the market is divided into chemotherapy and targeted therapy. The chemotherapy is anticipated to account for a key share and is anticipated to grow at a robust rate during the forecast period. Chemotherapy drugs, such as cladribine and pentostatin, are considered as an initial treatment option for most individuals with hairy cell leukemia. This factor is driving the segment growth. However, the targeted therapy segment is expected to grow at a healthy CAGR owing to ongoing R&D activities for the hairy cell leukemia treatment.
North America to account a large market share
On the basis of regions, the market is segregated into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America to account for a large market share owing to advancements in technologies, high incidence, and increasing geriatric population. Conversely, the market in Asia Pacific is expected to register a substantial growth rate in global hairy cell leukemia market during the forecast period.
Segments
Segments Covered in the Report
The global hairy cell leukemia market has been segmented on the basis of
Therapies
- Chemotherapy
- Targeted Therapy
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Hoffmann-La Roche Ltd
- Janssen Global Services LLC
- Dr. Reddy's Laboratories
- Emcure Pharmaceuticals
- Amgen Inc.
- Hospira
- Astex Therapeutics
- Pfizer Inc
- AstraZeneca plc
- BioGenomics Limited
- Incyte Corp
- Merck & Co Inc
- Genentech
- bluebird bio
- Beam Therapeutics
- Mission Bio
- Roivant Sciences Inc.
- Humanigen
- Fate Therapeutics
- Kronos Bio
- Tasso
- PTC Therapeutics
- Quantgene
- Syros Pharmaceuticals
- Oncoternal
- GlycoMimetics
- Notable Labs
- Nuprobe
- CARsgen
- Twinstrand Biosciences Inc.
Competitive Landscape
The major players of the market are Hoffmann-La Roche Ltd, Janssen Global Services LLC, Dr.Reddy's Laboratories, Emcure Pharmaceuticals, Amgen Inc., Hospira, Astex Therapeutics, Pfizer Inc, AstraZeneca plc, BioGenomics Limited, Incyte Corp, Merck & Co Inc, Genentech, bluebird bio, Beam Therapeutics, Mission Bio, Roivant Sciences Inc., Humanigen, Fate Therapeutics, Kronos Bio, Tasso, PTC Therapeutics, Quantgene, Syros Pharmaceuticals, Oncoternal, GlycoMimetics, Notable Labs, Nuprobe, CARsgen, and Twinstrand Biosciences Inc.
Companies are focusing on innovation, partnerships, and acquisitions to expand their market share.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hairy Cell Leukemia Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Hairy Cell Leukemia Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Hairy Cell Leukemia Market - Supply Chain
4.5. Global Hairy Cell Leukemia Market Forecast
4.5.1. Hairy Cell Leukemia Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Hairy Cell Leukemia Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Hairy Cell Leukemia Market Absolute $ Opportunity
5. Global Hairy Cell Leukemia Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Hairy Cell Leukemia Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Hairy Cell Leukemia Demand Share Forecast, 2019-2026
6. North America Hairy Cell Leukemia Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Hairy Cell Leukemia Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Hairy Cell Leukemia Demand Share Forecast, 2019-2026
7. Latin America Hairy Cell Leukemia Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Hairy Cell Leukemia Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Hairy Cell Leukemia Demand Share Forecast, 2019-2026
8. Europe Hairy Cell Leukemia Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Hairy Cell Leukemia Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Hairy Cell Leukemia Demand Share Forecast, 2019-2026
9. Asia Pacific Hairy Cell Leukemia Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Hairy Cell Leukemia Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Hairy Cell Leukemia Demand Share Forecast, 2019-2026
10. Middle East & Africa Hairy Cell Leukemia Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Hairy Cell Leukemia Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Hairy Cell Leukemia Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Hairy Cell Leukemia Market: Market Share Analysis
11.2. Hairy Cell Leukemia Distributors and Customers
11.3. Hairy Cell Leukemia Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Hoffmann-La Roche Ltd
11.4.2. Janssen Global Services LLC
11.4.3. Dr. Reddy's Laboratories
11.4.4. Emcure Pharmaceuticals
11.4.5. Amgen Inc.
11.4.6. Hospira
11.4.7. Astex Therapeutics
Segments Covered in the Report
The global hairy cell leukemia market has been segmented on the basis of
Therapies
- Chemotherapy
- Targeted Therapy
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Hoffmann-La Roche Ltd
- Janssen Global Services LLC
- Dr. Reddy's Laboratories
- Emcure Pharmaceuticals
- Amgen Inc.
- Hospira
- Astex Therapeutics
- Pfizer Inc
- AstraZeneca plc
- BioGenomics Limited
- Incyte Corp
- Merck & Co Inc
- Genentech
- bluebird bio
- Beam Therapeutics
- Mission Bio
- Roivant Sciences Inc.
- Humanigen
- Fate Therapeutics
- Kronos Bio
- Tasso
- PTC Therapeutics
- Quantgene
- Syros Pharmaceuticals
- Oncoternal
- GlycoMimetics
- Notable Labs
- Nuprobe
- CARsgen
- Twinstrand Biosciences Inc.
The major players of the market are Hoffmann-La Roche Ltd, Janssen Global Services LLC, Dr.Reddy's Laboratories, Emcure Pharmaceuticals, Amgen Inc., Hospira, Astex Therapeutics, Pfizer Inc, AstraZeneca plc, BioGenomics Limited, Incyte Corp, Merck & Co Inc, Genentech, bluebird bio, Beam Therapeutics, Mission Bio, Roivant Sciences Inc., Humanigen, Fate Therapeutics, Kronos Bio, Tasso, PTC Therapeutics, Quantgene, Syros Pharmaceuticals, Oncoternal, GlycoMimetics, Notable Labs, Nuprobe, CARsgen, and Twinstrand Biosciences Inc.
Companies are focusing on innovation, partnerships, and acquisitions to expand their market share.
Our Clients
Related Reports
Some other reports from this category!
